Older adults with an eGFR of 30 to 59 and less than 30 mL/min/1.73 m2 had a 1.7- and 2.6-fold fold higher risk of dementia, respectively, compared with those who had normal kidney function (eGFR 90-104 mL/min/1.73 m2).
Some Black medication users reclassified to lower eGFR for which dose adjustment or discontinuation is recommended
Non-linear renal function decline frequently occurs in patients with type 2 diabetes and is associated with faster progression to end-stage kidney disease.
In a study comparing the effect of 9 oral nonsteroidal anti-inflammatory drugs on kidney function, ibuprofen conferred the lowest risk for incident eGFR less than 60 mL/min/1.73 m2 and an eGFR decline of 30% or greater.
For patients weighing at least 50kg, Injectafer may be administered as a single dose option of 15mg/kg body weight up to a maximum of 1000mg intravenously.
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
The approval was based on data from the DAPA-CKD trial, which compared dapagliflozin, an SGLT2 inhibitor, to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
The association of pulmonary hypertension with an increased risk for kidney failure in older adults with chronic kidney disease is a novel finding.
Vadadustat and darbepoetin alfa had similar hematologic efficacy in patients with nondialysis-dependent CKD (NDD-CKD) and those on dialysis, but vadadustat was associated with a higher risk of major adverse cardiovascular events in patients with NDD-CKD.
The NDA submission includes data from the phase 3 CARDINAL trial that evaluated the efficacy and safety of bardoxolone in 157 patients with CKD caused by Alport syndrome.
